| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066550A2 Compounds for pdt |
| 09/13/2001 | WO2001066545A2 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY |
| 09/13/2001 | WO2001066540A1 Imidazol-2-carboxamide derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066539A1 Imidazol derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066148A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066139A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 09/13/2001 | WO2001066131A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase |
| 09/13/2001 | WO2001066126A1 Sialoadhesin factor-2 antibodies |
| 09/13/2001 | WO2001066125A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
| 09/13/2001 | WO2001066123A2 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066100A2 Pharmaceutical composition |
| 09/13/2001 | WO2001066099A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 09/13/2001 | WO2001066089A2 Pharmaceutical compositions comprising cannabis |
| 09/13/2001 | WO2001065911A2 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | WO2001030759A3 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028993A3 Tyrosine kinase inhibitors |
| 09/13/2001 | WO2001028498A3 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 09/13/2001 | WO2001028497A3 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 09/13/2001 | WO2001028492A3 Polyanhydrides with biologically active degradation products |
| 09/13/2001 | WO2001019542A8 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/13/2001 | WO2001009169A3 Cysteine protease inhibitors |
| 09/13/2001 | WO2001005805A3 Novel c-19-halogen-substituted, 5-substituted, 5-substituted or 6,10 carbocyclically condensed steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 09/13/2001 | WO2001004282A3 Replication-competent anti-cancer vectors |
| 09/13/2001 | WO2000043790A9 Compositions and methods for the diagnosis and treatment of tumor |
| 09/13/2001 | WO2000040701A9 Non-myeloablative tolerogenic treatment |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | WO1997014683A3 Phenanthridine derivatives, methods of producing them and medicaments containing phenanthridine derivatives |
| 09/13/2001 | US20010021772 Vascular endothelial growth factor |
| 09/13/2001 | US20010021720 Synergistic mixture of docletaxel and phosphodiesterase inhibitor |
| 09/13/2001 | US20010021719 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents |
| 09/13/2001 | US20010021717 Hydroxylation activated prodrugs |
| 09/13/2001 | US20010021708 Acylurea compound containing imidazolidine ring |
| 09/13/2001 | US20010021704 Active compounds with cytostatic activity, biological electron acceptors, and pharmaceutically customary additives |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021507 Renal nuclear matrix protein able to differentiate cancerous renal cell from normal renal cells; useful for diagnosis and producing treatment for cell proliferative disorders of the kidney |
| 09/13/2001 | US20010021397 Solvent extraction from yeast |
| 09/13/2001 | US20010021395 Mixture of nucleic acid and anticancer agent |
| 09/13/2001 | DE19954228A1 New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis |
| 09/13/2001 | CA2403029A1 Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids |
| 09/13/2001 | CA2402896A1 Polypeptide inducing apoptosis |
| 09/13/2001 | CA2402466A1 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | CA2402433A1 Compounds for pdt |
| 09/13/2001 | CA2402211A1 Phosphatidyl serine receptors and uses thereof |
| 09/13/2001 | CA2402081A1 A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| 09/13/2001 | CA2402027A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2401239A1 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | CA2400711A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/12/2001 | EP1132401A1 HUMAN PROTEINS STAM2a AND STAM2b AND cDNAS ENCODING THESE MOLECULES |
| 09/12/2001 | EP1132395A2 Process for the preparation of a pharmacologically active peptide |
| 09/12/2001 | EP1132388A2 Hexahydropyrazolo[4,3-c]pyridine metabolites |
| 09/12/2001 | EP1132380A1 E-Isomeric fullerene derivatives |
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131463A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption |
| 09/12/2001 | EP1131461A1 N-terminally truncated her-2/neu protein as a cancer prognostic indicator |
| 09/12/2001 | EP1131458A1 Viral vectors with late transgene expression |
| 09/12/2001 | EP1131457A1 Systemic viral/ligand gene delivery system and gene therapy |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131443A2 Human hydrolase proteins |
| 09/12/2001 | EP1131429A1 Calcium binding protein |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131426A2 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 09/12/2001 | EP1131417A2 Engineered cytotoxic ribonuclease |
| 09/12/2001 | EP1131408A2 Cells, culture methods, and their use in autologous transplantation therapy |
| 09/12/2001 | EP1131350A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 09/12/2001 | EP1131348A1 Regulatory/unfolding peptides of ezrin |
| 09/12/2001 | EP1131347A2 Product |
| 09/12/2001 | EP1131344A2 Retro-inversion peptides that target git transport receptors and related methods |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131337A1 Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors |
| 09/12/2001 | EP1131327A1 Prostaglandin conjugates for treating or preventing bone disease |
| 09/12/2001 | EP1131317A1 Method for preparing (2s)-1- (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
| 09/12/2001 | EP1131316A2 Improved chemical process and pharmaceutical formulation |
| 09/12/2001 | EP1131315A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 09/12/2001 | EP1131314A1 Compounds having cytokine inhibitory activity |
| 09/12/2001 | EP1131310A1 Chrystals of 5- 6-(2-fluorobenzyl)oxy-2-naphthyl methyl]-2,4-thiazolidinedione |
| 09/12/2001 | EP1131304A1 N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131297A1 Certain substituted caprolactams, pharmaceutical compositions containing them and their use in treating tumors |
| 09/12/2001 | EP1131106A1 Compositions and methods for producing vascular occlusion |
| 09/12/2001 | EP1131103A1 Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 09/12/2001 | EP1131099A2 Noninvasive vascular therapy |
| 09/12/2001 | EP1131097A1 Anti-icam-r antibody-induced apoptosis |
| 09/12/2001 | EP1131096A1 Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants |
| 09/12/2001 | EP1131095A1 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| 09/12/2001 | EP1131093A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 09/12/2001 | EP1131088A2 NF-$g(k)B ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES |
| 09/12/2001 | EP1131087A2 Methods of alleviating cancer symptoms |